A new multicenter randomized clinical trial is underway to compare the performance and safety of two wound debridement devices: Debrisoft® Duo and Debrisoft® Pad. This study, sponsored by Lohmann & Rauscher and AXCELLANT, aims to assess whether the two-sided debridement pad (Debrisoft® Duo) is as effective and safe as the one-sided pad (Debrisoft® Pad) for various wound types.
What is the study about?
The clinical trial, titled “Multicenter, Randomized, Non-inferiority Study to Compare the Performance and Safety of Debrisoft® Duo With Debrisoft® Pad in the Debridement of Wounds,” is designed to determine whether Debrisoft® Duo is at least as effective and safe as Debrisoft® Pad. Both devices are used to remove wound debris, a critical process for optimal wound healing.
Safety and performance data from this study could provide further insights into wound care management, especially for healthcare professionals and regulatory teams evaluating dressing options for their patients. Recruitment for the trial is currently ongoing.
Which wound conditions are included?
The study includes a broad range of wound types that require debridement. These conditions are:
- Diabetic ulcers
- Arterial ulcers
- Venous ulcers
- Pressure ulcers
- Postoperative wounds healing by secondary intention
- Burns and scalds
- Epidermolysis bullosa (EB)
- Traumatic wounds
- Surgical wounds
This diversity ensures that the devices are tested across various clinical scenarios, allowing the study’s findings to apply broadly to real-world wound care settings.
How are the devices being compared?
The trial employs a non-inferiority design to evaluate the safety and effectiveness of the two devices. Debrisoft® Duo features a two-sided debridement pad, while Debrisoft® Pad has a one-sided configuration. The inclusion of two types of pads ensures thorough clinical evaluation of multiple device designs for wound debridement.
Patients enrolled in the trial will receive one of the two devices during treatment. Outcomes monitored include wound cleanliness, patient tolerance, device usability, and adverse events, aligned with regulatory performance metrics for medical devices under MDR Annex XIV.
FAQ
1. What are Debrisoft® Duo and Debrisoft® Pad?
Both Debrisoft® Duo and Debrisoft® Pad are wound debridement devices. They are used to remove debris, necrotic tissue, and exudate, aiding the wound healing process.
2. Who sponsors this trial?
The study is sponsored by Lohmann & Rauscher, a prominent wound care company, and AXCELLANT.
3. How can healthcare providers benefit from this study?
The data generated may help healthcare providers choose the most appropriate debridement device for their clinical needs.
4. When will results be available?
No specific date is provided, but results will likely follow the completion of the trial’s recruitment and primary analysis phases.
Conclusion
This ongoing trial represents a significant development in evaluating wound care technologies. Regulatory and clinical teams should monitor its outcomes to guide device selection and ensure compliance with medical device performance standards. Healthcare professionals and researchers involved in wound care may find the study’s conclusions particularly relevant for optimizing treatment strategies.
Disclaimer
The information provided in this article is for informational purposes only and does not constitute legal or clinical advice. Regulatory professionals should verify specific requirements with applicable authorities.
Announcement Line
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07312513?term=medical+device